<DOC>
	<DOCNO>NCT03095092</DOCNO>
	<brief_summary>The purpose study investigate effect food pharmacokinetics single 400 mg dose BIA 6-512 ( trans-resveratrol ) healthy volunteer</brief_summary>
	<brief_title>Effect Food BIA 6-512 ( Trans-resveratrol )</brief_title>
	<detailed_description>Single-centre , open-label , randomised , two-way crossover study 24 healthy male female subject . The study consist 2 single-dose period separate washout 7 day . Eligible subject admit UFH day ( Day 0 ) prior receive dose study medication ( Day 1 ) . On morning next day ( Day 1 ) , BIA 6-512 400 mg dose administer follow either standard breakfast ( Test ) least 8 hour fast ( Reference ) . Subjects remain confined UFH admission ( Day 0 ) least 24 h post dose ( Day 2 ) ; , discharge return second treatment period follow-up visit .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , 12lead ECG . Subjects clinical laboratory test result clinically acceptable screen admission first treatment period . Subjects negative test HBsAg , antiHCVAb HIV1 HIV2 Ab screen . Subjects negative screen alcohol drug abuse screen admission treatment period . Subjects nonsmoker smoke â‰¤ 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If female ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence . ( If female ) She negative urine pregnancy test screen admission treatment period . Subjects conform inclusion criterion , OR Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant drug food hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 21 unit alcohol week . Subjects significant infection know inflammatory process screen first admission . Subjects acute gastrointestinal symptom time screen first admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects use medicine within 2 week first admission , opinion investigator , may affect safety study assessment . Subjects use investigational drug participate clinical trial within 2 month first admission . Subjects donate received blood blood product within previous 2 month prior screen . Subjects vegetarian , vegan medical dietary restriction . Subjects communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method ( doublebarrier , intrauterine device abstinence ) use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>